PL2801625T3 - Molekularne, genetyczne podejście do leczenia i diagnozy uzależnienia od alkoholu i leków - Google Patents

Molekularne, genetyczne podejście do leczenia i diagnozy uzależnienia od alkoholu i leków

Info

Publication number
PL2801625T3
PL2801625T3 PL14173142T PL14173142T PL2801625T3 PL 2801625 T3 PL2801625 T3 PL 2801625T3 PL 14173142 T PL14173142 T PL 14173142T PL 14173142 T PL14173142 T PL 14173142T PL 2801625 T3 PL2801625 T3 PL 2801625T3
Authority
PL
Poland
Prior art keywords
diagnosis
alcohol
treatment
molecular genetic
drug dependence
Prior art date
Application number
PL14173142T
Other languages
English (en)
Inventor
Bankole A. Johnson
Original Assignee
University Of Virginia Patent Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Virginia Patent Foundation filed Critical University Of Virginia Patent Foundation
Publication of PL2801625T3 publication Critical patent/PL2801625T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/172Haplotypes
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Addiction (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
PL14173142T 2010-07-02 2011-07-01 Molekularne, genetyczne podejście do leczenia i diagnozy uzależnienia od alkoholu i leków PL2801625T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US36120310P 2010-07-02 2010-07-02
US201161429416P 2011-01-03 2011-01-03
US201161488328P 2011-05-20 2011-05-20
EP14173142.2A EP2801625B1 (en) 2010-07-02 2011-07-01 Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
EP11801503.1A EP2588630A4 (en) 2010-07-02 2011-07-01 MOLECULAR GENETIC APPROACH FOR THE TREATMENT AND DIAGNOSIS OF ALCOHOL AND MEDICINE DEPENDENCE

Publications (1)

Publication Number Publication Date
PL2801625T3 true PL2801625T3 (pl) 2018-06-29

Family

ID=45402467

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14173142T PL2801625T3 (pl) 2010-07-02 2011-07-01 Molekularne, genetyczne podejście do leczenia i diagnozy uzależnienia od alkoholu i leków

Country Status (17)

Country Link
US (9) US8753815B2 (pl)
EP (2) EP2588630A4 (pl)
AU (1) AU2011274355B2 (pl)
CA (1) CA2804174A1 (pl)
CY (1) CY1120057T1 (pl)
DK (1) DK2801625T3 (pl)
EA (1) EA024450B1 (pl)
ES (1) ES2664083T3 (pl)
HR (1) HRP20180193T1 (pl)
HU (1) HUE035574T2 (pl)
IL (2) IL278149B2 (pl)
LT (1) LT2801625T (pl)
NZ (3) NZ605709A (pl)
PL (1) PL2801625T3 (pl)
SI (1) SI2801625T1 (pl)
UA (1) UA116615C2 (pl)
WO (1) WO2012003462A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2255184T3 (pl) 2008-02-28 2013-12-31 Univ Virginia Patent Foundation Gen transportera serotoniny i leczenie alkoholizmu
PL2801625T3 (pl) 2010-07-02 2018-06-29 University Of Virginia Patent Foundation Molekularne, genetyczne podejście do leczenia i diagnozy uzależnienia od alkoholu i leków
EP3045173A3 (en) 2011-09-09 2016-09-14 The University of Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
WO2013138811A1 (en) * 2012-03-16 2013-09-19 Life Of Purpose, Llc Niche-specific treatment infrastructure continuum
US11610144B2 (en) * 2018-02-02 2023-03-21 BioRealm LLC Biosignature discovery for substance use disorder using statistical learning
WO2026011119A1 (en) * 2024-07-05 2026-01-08 Adial Pharmaceuticals, Inc. Ondansetron treatment of alcohol use disorder

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA219554A (en) 1922-06-13 Edward A. Taft Knot tying implement
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US5550021A (en) 1990-02-07 1996-08-27 Board Of Regents, The University Of Texas System Allelic diagnosis of susceptibility to compulsive disorder
RU2075978C1 (ru) 1994-03-21 1997-03-27 Владислав Ефимович Шофер Способ лечения больных хроническим алкоголизмом
EP0714663A3 (en) 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
EP0945133A1 (en) 1998-03-26 1999-09-29 Lipha Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator
US6200604B1 (en) 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
US20040167164A1 (en) 1998-05-05 2004-08-26 Jose Pozuelo Compositions and methods for treating particular chemical addictions and mental illnesses
US6287765B1 (en) 1998-05-20 2001-09-11 Molecular Machines, Inc. Methods for detecting and identifying single molecules
SE9803240D0 (sv) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
CA2362533A1 (en) 1999-02-22 2000-08-31 Variagenics, Inc. Gene sequence variations with utility in determining the treatment of disease
ATE294577T1 (de) 1999-02-24 2005-05-15 Univ Cincinnati Verwendung von sulfamat derivaten zur behandlung von impulsiven störungen
WO2002026118A2 (en) 2000-09-29 2002-04-04 New Health Sciences, Inc. Systems and methods for assessing vascular effects of a treatment
US7122308B2 (en) 2001-02-16 2006-10-17 Centre For Addiction And Mental Health Detection of antidepressant induced mania
US7033771B2 (en) 2001-05-08 2006-04-25 Takeda Pharmaceutical Company Limited Use of insulin response modulators in the treatment of diabetes and insulin resistance
EP1262196A3 (en) 2001-05-23 2002-12-18 Pfizer Products Inc. Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
EP1423116A1 (en) 2001-08-14 2004-06-02 Biotie Therapies Corp. Method of treating alcoholism or alcohol abuse
WO2003018843A1 (en) 2001-08-21 2003-03-06 Smithkline Beecham Corporation Gene polymorphisms and response to treatment
US20060173064A1 (en) 2001-08-24 2006-08-03 Lippa Arnold S (-)-1-(3,4-Dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders
AU2002348135A1 (en) 2001-10-31 2003-05-12 Recovery Pharmaceuticals, Inc. Methods for the treatment of addiction
AU2003240253A1 (en) * 2002-05-15 2003-12-02 Epidauros Biotechnologie Ag Polymorphisms in the human gene for htr3b and their use in diagnostic and therapeutic applications
WO2003100091A1 (en) * 2002-05-24 2003-12-04 Epidauros Biotechnologie Ag Means and methods for improved treatment using 'setrones'
AT414215B (de) 2003-02-12 2006-10-15 Peter Ziger Anlage zur plasmaprozessierung
HUE034290T2 (en) 2003-04-29 2018-02-28 Orexigen Therapeutics Inc Preparations containing opioid antagonist and bupropion to affect weight loss
GB0316915D0 (en) 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
US7163969B2 (en) 2003-10-14 2007-01-16 Stockhausen, Inc. Superabsorbent polymer aqueous paste and coating
US20050245461A1 (en) 2004-03-19 2005-11-03 Elliot Ehrich Methods for treating alcoholism
WO2007009691A2 (en) 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Combination of substituted pyrazolines and anti -addictive agent
WO2007039123A2 (en) 2005-09-22 2007-04-12 Smithkline Beecham Corporation Combination therapy comprising an nk-3 antagonist and an antipsychotic agent
CA2623072A1 (en) 2005-09-26 2007-04-05 Avigen, Inc. Use of ibudilast for treating drug and behavioral addictions
US20070196841A1 (en) * 2006-01-20 2007-08-23 Gualberto Ruano Physiogenomic method for predicting response to diet
US8026059B2 (en) 2006-02-15 2011-09-27 The Regents Of The University Of California Treatment response in generalized social phobia
US20070292880A1 (en) 2006-05-05 2007-12-20 Robert Philibert Compositions and methods for detecting predisposition to a substance use disorder or to a mental illness or syndrome
US20080004260A1 (en) 2006-06-29 2008-01-03 Transcept Pharmaceuticals, Inc. Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
US7645750B2 (en) * 2006-12-13 2010-01-12 Yung Shin Pharmaceutical Ind. Co., Ltd. Method of treating symptoms of hormonal variations
JP2010513569A (ja) 2006-12-19 2010-04-30 ユニバーシティ オブ バージニア パテント ファウンデーション アルコール摂取に対するトピラメートおよびオンダンセトロンの併用効果
US20100076006A1 (en) 2007-01-31 2010-03-25 University Of Virginia Patent Foundation Topiramate Plus Naltrexone for the Treatment of Addictive Disorders
US20080228700A1 (en) 2007-03-16 2008-09-18 Expanse Networks, Inc. Attribute Combination Discovery
US20100266692A1 (en) 2007-07-13 2010-10-21 Corey Jay Bloom Nanoparticles comprising a non-ionizable polymer and an anionic cellulosic polymer
US20110264374A1 (en) 2007-08-21 2011-10-27 University Of Virginia Patent Foundation Method, Computer Program Product and System for Individual Assessment of Alcohol Sensitivity
WO2009029308A1 (en) 2007-08-27 2009-03-05 University Of Virginia Patent Foundation Medication combinations for the treatment of alcoholism and drug addiction
PL2255184T3 (pl) 2008-02-28 2013-12-31 Univ Virginia Patent Foundation Gen transportera serotoniny i leczenie alkoholizmu
US20090269773A1 (en) 2008-04-29 2009-10-29 Nodality, Inc. A Delaware Corporation Methods of determining the health status of an individual
EP2425013A1 (en) 2009-05-01 2012-03-07 University Of Virginia Patent Foundation Serotonin transporter gene and treatment of alcoholism
PL2801625T3 (pl) 2010-07-02 2018-06-29 University Of Virginia Patent Foundation Molekularne, genetyczne podejście do leczenia i diagnozy uzależnienia od alkoholu i leków
EP3045173A3 (en) 2011-09-09 2016-09-14 The University of Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
US10997121B1 (en) 2020-07-17 2021-05-04 Snowflake Inc. Attachable-and-detachable database sessions

Also Published As

Publication number Publication date
US20200316028A1 (en) 2020-10-08
US9539242B2 (en) 2017-01-10
EP2588630A4 (en) 2013-12-25
US10603307B2 (en) 2020-03-31
IL262874B (en) 2021-02-28
IL278149B1 (en) 2023-11-01
DK2801625T3 (en) 2018-02-05
HUE035574T2 (en) 2018-05-28
LT2801625T (lt) 2018-03-12
CA2804174A1 (en) 2012-01-05
US20170239222A1 (en) 2017-08-24
WO2012003462A4 (en) 2012-03-22
IL278149B2 (en) 2024-03-01
US20210023058A1 (en) 2021-01-28
US20230263776A1 (en) 2023-08-24
US20140288139A1 (en) 2014-09-25
CY1120057T1 (el) 2018-12-12
EA024450B1 (ru) 2016-09-30
US12226401B2 (en) 2025-02-18
EP2801625B1 (en) 2017-11-01
EP2801625A1 (en) 2014-11-12
SI2801625T1 (en) 2018-04-30
IL262874A (en) 2018-12-31
US11324723B2 (en) 2022-05-10
US11957664B2 (en) 2024-04-16
NZ621356A (en) 2015-08-28
US20230241032A1 (en) 2023-08-03
IL278149A (en) 2020-11-30
NZ605709A (en) 2014-08-29
US20240277671A1 (en) 2024-08-22
EA201390017A1 (ru) 2013-06-28
AU2011274355A1 (en) 2013-01-24
US20130012559A1 (en) 2013-01-10
ES2664083T3 (es) 2018-04-18
US11116753B2 (en) 2021-09-14
AU2011274355B2 (en) 2016-10-27
US12274692B2 (en) 2025-04-15
HRP20180193T1 (hr) 2018-04-06
EP2588630A1 (en) 2013-05-08
WO2012003462A1 (en) 2012-01-05
US8753815B2 (en) 2014-06-17
US12150931B2 (en) 2024-11-26
US20230014787A1 (en) 2023-01-19
UA116615C2 (uk) 2018-04-25
NZ621352A (en) 2015-08-28

Similar Documents

Publication Publication Date Title
IL278149A (en) A molecular genetic approach to the treatment and diagnosis of alcohol and drug dependence
IL273107B (en) Pharmaceutical preparations of human rpe cells and their use
EP2413917A4 (en) DRUG DELIVERY SYSTEM AND METHODS OF USING THE SAME
ZA201301601B (en) Treatment of diseases
EP2521553A4 (en) METHODS AND COMPOSITIONS FOR THE DEVELOPMENT OF TARGETED MEDICAMENTS
EP2531908A4 (en) SEARCH REQUEST PROCESSING
GB201302653D0 (en) Pharmaceutical compositions and methods of treatment
GB2496794B (en) Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
ZA201300218B (en) Treatment of blood cancer
IL224544B (en) Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
GB201104473D0 (en) Improved pharmaceutical compositions and methods of delivery
PL2464342T3 (pl) Formulacje farmaceutyczne do zapobiegania niewłaściwemu użyciu leków medycznych
EP2585828A4 (en) METHOD FOR THE TREATMENT OF PATIENTS WITH IMMUNE SYSTEM DISEASES
EP2626071A4 (en) APPLICATIONS OF ARCTIGENIN FOR THE FORMULATION OF MEDICAMENTS FOR THE PROPHYLAXIS OR THE TREATMENT OF DISEASES RELATED TO THE REDUCTION OF RED BLOOD BODIES
PL2582366T3 (pl) Kombinacja farmaceutyczna do leczenia bólu
PL2613798T3 (pl) Zastosowanie lizosomalnej kwaśnej lipazy do leczenia niedoboru lizosomalnej kwaśnej lipazy u pacjentów
ITTO20110631A1 (it) Composizione farmaceutica di combinazione e metodi per trattare patologie del sistema genitourinario
ZA201502332B (en) Medicinal treatment of dermal diseases in companion animals with norketotifen
SG11201401038VA (en) Isolating and therapeutic use of perivascular medicinal cells
EP2744512A4 (en) Use of neuregulin-4 for treatment of inflammatory bowel disease and necrotizing enterocolitis
EP2531202A4 (en) USE OF HEPARIN-BASED ORAL PREPARATIONS FOR TREATING DISEASES AND DISEASES OF THE URINARY TRACT
PT2632885T (pt) Compostos carboxilatos de fenilcetona e usos farmacêuticos destes
EP2650292A4 (en) THIAZOLAMINE DERIVATIVE AND ITS PHARMACEUTICAL APPLICATIONS FOR SMALL RNA VIRAL INFECTIONS
HK1184504A (en) Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
IL222690A0 (en) Treatment of autoimmune diseases